Accretive Transaction with Combined Companies’ Pro-Forma Revenue in Excess of $70.00 Million and EBITDA(1) in Excess of $15.75 Million (TTM Sept 30, 2025) MISSISSAUGA, Ontario, Feb. 09, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture (TSXV): RX) announced today that it has entered into a Share Purchase Agreement (“SPA”) dated February 8, 2026 to acquire Oral Science Inc. (“Oral Science”), a privately-owned Canadian distributor of specialized healthcare products for dental hygiene and oral he ...

Core Viewpoint - BioSyent Inc. has declared a quarterly dividend of $0.055 per common share, marking a 10% increase from the previous quarter's dividend of $0.05 per share, reflecting the company's commitment to returning value to shareholders [1]. Company Overview - BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company listed on the TSX Venture Exchange under the symbol "RX". The company focuses on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record of improving patient lives [2]. - The company supports healthcare professionals by marketing its products through community, specialty, and international business units [2]. Financial Information - As of the date of the press release, BioSyent has 11,263,255 common shares outstanding [3].

MISSISSAUGA, Ontario, Jan. 29, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. This first quarter 2026 dividend represents a 10% increase from the fourth quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible ...

PresentationRené GoehrumChairman, CEO & President Hello, and welcome to the Q3 and YTD 2025 Results Presentation for BioSyent Inc. My name is Rene Goehrum, and I'm the President and CEO of the company. Before I dive into the presentation, I'd just like to draw your attention to our forward-looking statements disclaimer. I'm likely to make some. So let's start the presentation by taking a look at our revenue and profitability. This slide shows you a sales performance of over $12 million in the third quarter ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - BioSyent Inc. reported strong financial results for Q3 and YTD 2025, with total company sales increasing by 28% in Q3 and 27% year-to-date, driven by growth in both Canadian and international pharmaceutical sales [1][2] Financial Performance - Canadian Pharma Sales reached CAD 9,864,254 in Q3 2025, a 19% increase compared to Q3 2024, and CAD 28,351,130 year-to-date, up 16% [1] - International Pharma Sales surged to CAD 1,153,742 in Q3 2025, a remarkable 94% increase year-over-year, and CAD 3,134,572 year-to-date, reflecting a 316% growth [1] - Legacy Business Sales also saw significant growth, with Q3 2025 sales of CAD 1,203,808, an 83% increase, and year-to-date sales of CAD 1,894,358, up 73% [1] - Total Company Sales for Q3 2025 were CAD 12,221,804, a 28% increase, and CAD 33,380,060 year-to-date, a 27% increase [1][7] - EBITDA for Q3 2025 was CAD 3,632,399, a 27% increase, with a consistent EBITDA margin of 30% [1][7] - Net Income After Taxes (NIAT) for Q3 2025 was CAD 2,682,340, a 16% increase, and CAD 7,020,444 year-to-date, up 24% [1][7] Business Highlights - The company’s products, FeraMAX® and Tibella® / Tibelia®, continue to show profitable sales growth both domestically and internationally [2] - The acquisition of worldwide rights to Tibella® / Tibelia® in September 2024 has met initial expectations for sales and profit growth [2] Shareholder Information - BioSyent has declared a quarterly cash dividend of CAD 0.05 per common share, with the next payment scheduled for December 15, 2025 [5] - The company repurchased 19,500 common shares under a Normal Course Issuer Bid (NCIB) during YTD 2025 [5] - As of September 30, 2025, the company had 11,262,282 common shares outstanding [6] Balance Sheet Overview - Total assets as of September 30, 2025, were CAD 47,785,381, a 16% increase from CAD 41,359,450 at the end of 2024 [9] - Current assets increased by 47% to CAD 35,969,294, driven by a significant rise in trade and other receivables [9] - Total equity rose by 14% to CAD 39,902,869, reflecting the company's strong financial position [9]

Core Points - BioSyent Inc. has declared a quarterly dividend of $0.05 per common share, payable on December 15, 2025, to shareholders of record on November 28, 2025 [1] - The dividend for the fourth quarter of 2025 is consistent with the third quarter of 2025, indicating stable dividend policy [1] - The dividend qualifies as an 'eligible dividend' for Canadian income tax purposes [1] Company Overview - BioSyent Inc. is a profitable growth-oriented specialty pharmaceutical company listed on the TSX Venture Exchange under the symbol "RX" [2] - The company focuses on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record [2] - BioSyent markets its products through community, specialty, and international business units to support healthcare professionals [2] Share Information - As of the date of the press release, BioSyent has 11,262,282 common shares outstanding [3]

MISSISSAUGA, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and nine months ended September 30, 2025 on Thursday, November 20, 2025 after market hours. A presentation on the Company’s third quarter and year-to-date 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Excha ...

Core Insights - BioSyent Inc. reported strong financial performance for Q2 and H1 2025, with overall sales growth of 14% and net profit growth of 28% [1][5] - The Canadian Pharma segment saw a 9% increase in sales, while the International Pharma segment experienced a significant 183% increase in Q2 2025 [1][5] - The company aims for long-term value creation through portfolio diversification and profitable growth [1] Financial Performance - Total Company Sales for Q2 2025 reached CAD 10,179,296, a 14% increase compared to Q2 2024, and CAD 21,158,256 for H1 2025, reflecting a 27% increase from H1 2024 [5][9] - Net Income After Taxes for Q2 2025 was CAD 2,018,171, up 28% from Q2 2024, and CAD 4,338,104 for H1 2025, a 30% increase from H1 2024 [5][9] - EBITDA for Q2 2025 was CAD 2,760,149, representing a 35% increase year-over-year, and CAD 5,961,796 for H1 2025, a 40% increase [5][9] Balance Sheet Highlights - As of June 30, 2025, total assets increased to CAD 43,495,489, a 5% rise from December 31, 2024 [7][10] - Cash, cash equivalents, and short-term investments rose by 28% to CAD 20,364,392 [7] - Trade and other receivables increased by 67% to CAD 4,867,796, while inventory decreased by 9% to CAD 4,860,613 [7] Shareholder Returns - The company repurchased 19,500 common shares during H1 2025 under a Normal Course Issuer Bid [5] - Quarterly cash dividends of CAD 0.05 per common share were paid on March 14, 2025, and June 13, 2025, with a subsequent dividend declared for September 15, 2025 [5]

Company Overview - BioSyent Inc. is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record of improving patient lives [2] - The company markets its products through community, specialty, and international business units to support healthcare professionals [2] Dividend Announcement - BioSyent's Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on September 15, 2025, to shareholders of record at the close of business on August 29, 2025 [1] - This dividend for the third quarter of 2025 is consistent with the second quarter 2025 dividend of $0.05 per common share [1] - The dividend qualifies as an 'eligible dividend' for Canadian income tax purposes [1] Share Information - As of the date of the press release, BioSyent has 11,260,794 common shares outstanding [3]